Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb

Showing 15 posts of 146 posts found.

iqwigsmall

IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition

April 11, 2016
Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV

German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally …

News
bms_good

Bristol-Myers Squibb to acquire Padlock Therapeutics for up to $600m

March 23, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Padlock Therapeutics, rheumatoid arthritis

Bristol-Myers Squibb is to acquire Massachusetts-based auto-immune disease specialist Padlock Therapeutics in a deal worth up to $600 million. The …

News
drugs_generic

Delivering successful new drugs

March 1, 2016
Manufacturing and Production, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, patents, pharma

Pharma companies are struggling with challenges specific to their industry. Patents for many drugs, that had created massive amounts of …

Feature
viiv_healthcare

ViiV completes BMS HIV pipeline purchase

February 23, 2016
Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV

ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …

News
opdivo

UK lung cancer patients get early access to breakthrough BMS drug

February 5, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo

UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …

News
bms_logo_square

Europe approves BMS hep C drug for HIV and liver transplant patients

February 1, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, daclatasvir, daklinza

The European Commission has approved the expanded use of Bristol Myers-Squibb’s hepatitis C drug Daklinza (daclatasvir), to include liver transplant …

News
Empliciti pack shot

EMA fast-tracks BMS multiple myeloma drug

February 1, 2016
Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, EMA, Empliciti, myeloma

The EMA has recommended granting a marketing authorisation for Bristol Myers-Squibb and AbbVie’s immunotherapy Empliciti for the treatment of multiple myeloma. The …

News
FDA building

FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo

January 25, 2016
Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer

The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …

News
Opdivo

NICE ‘yes’ for BMS skin cancer drug Opdivo

January 22, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer

NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …

News
landing-hero-images1

ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs

December 18, 2015
Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare

Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …

News
NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

News

Bristol-Myers Squibb chooses UCLA as latest research partner

December 14, 2015
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla

Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …

News
Empliciti logo

FDA approves BMS and AbbVie’s Empliciti for multiple myeloma

December 1, 2015
Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma

The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …

News
Medicines Patent Pool

BMS and Medicines Patent Pool collaborate to increase Hep C medicine access

November 25, 2015
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C

The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …

News
BMS

Bristol-Myers Squibb in new oncology collaboration

November 25, 2015
Research and Development Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital

Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies.  The companies …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026